Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India.

Mukhopadhyay A, Dasgupta S, Mukhopadhyay S, Bose CK, Sarkar S, Gharami F, Koner S, Basak J, Roy UK.

Indian J Hematol Blood Transfus. 2012 Jun;28(2):82-8. doi: 10.1007/s12288-011-0108-9. Epub 2011 Sep 21.

3.

Spotlight on imatinib mesylate in chronic myeloid leukemia.

Curran MP, Croom KF, Goa KL.

BioDrugs. 2004;18(3):207-10. Review.

PMID:
15161340
4.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.

N Engl J Med. 2006 Dec 7;355(23):2408-17.

5.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

6.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators.

N Engl J Med. 2003 Mar 13;348(11):994-1004.

7.

[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].

Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.

Ai Zheng. 2004 Dec;23(12):1696-9. Chinese.

PMID:
15601563
8.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP; International Randomised Study of Interferon versus STI571 (IRIS) Study Group.

N Engl J Med. 2003 Oct 9;349(15):1423-32.

9.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
10.

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.

Clin Cancer Res. 2002 Jul;8(7):2177-87.

11.

Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

McCormack PL, Keam SJ.

BioDrugs. 2012 Feb 1;26(1):61-4. doi: 10.2165/11207640-000000000-00000.

PMID:
22233429
12.

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

McCormack PL, Keam SJ.

Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000. Review.

PMID:
21902298
13.

Imatinib: a review of its use in chronic myeloid leukaemia.

Moen MD, McKeage K, Plosker GL, Siddiqui MA.

Drugs. 2007;67(2):299-320. Review.

PMID:
17284091
14.

[Tyrosine kinase inhibitors for the treatment of CML].

Heim D.

Ther Umsch. 2006 Apr;63(4):249-54. Review. German.

PMID:
16689455
15.

Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib.

Junmei Z, Fengkuan Y, Yongping S, Baijun F, Yuzhang L, Lina L, Qinglan Z.

Springerplus. 2015 Apr 9;4:170. doi: 10.1186/s40064-015-0930-x. eCollection 2015.

16.

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.

Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M.

Blood. 2002 May 15;99(10):3547-53.

17.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

18.

Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME.

Blood. 2002 Jul 15;100(2):435-41.

19.

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.

Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.

Cancer. 2003 Dec 15;98(12):2636-42.

20.

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.

O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.

Cancer. 2003 Sep 1;98(5):888-93.

Supplemental Content

Support Center